Universe Cash from 2010 to 2026
| UPC Stock | USD 3.98 0.41 9.34% |
Cash | First Reported 2018-09-30 | Previous Quarter 33.6 M | Current Value 33.6 M | Quarterly Volatility 12.6 M |
Check Universe Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Universe Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 516.7 K or Interest Expense of 185.5 K, as well as many indicators such as Price To Sales Ratio of 9.0E-4, Dividend Yield of 0.0765 or PTB Ratio of 3.0E-4. Universe financial statements analysis is a perfect complement when working with Universe Pharmaceuticals Valuation or Volatility modules.
Universe | Cash | Build AI portfolio with Universe Stock |
Analyzing Universe Pharmaceuticals's Cash over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Cash has evolved provides context for assessing Universe Pharmaceuticals's current valuation and future prospects.
Latest Universe Pharmaceuticals' Cash Growth Pattern
Below is the plot of the Cash of Universe Pharmaceuticals over the last few years. Cash refers to the most liquid asset of Universe Pharmaceuticals, which is listed under current asset account on Universe Pharmaceuticals balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Universe Pharmaceuticals customers. The amounts must be unrestricted with restricted cash listed in a different Universe Pharmaceuticals account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Universe Pharmaceuticals' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Universe Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Cash | 10 Years Trend |
|
Cash |
| Timeline |
Universe Cash Regression Statistics
| Arithmetic Mean | 13,183,204 | |
| Geometric Mean | 9,239,968 | |
| Coefficient Of Variation | 99.00 | |
| Mean Deviation | 10,535,306 | |
| Median | 6,190,176 | |
| Standard Deviation | 13,050,993 | |
| Sample Variance | 170.3T | |
| Range | 37.4M | |
| R-Value | 0.75 | |
| Mean Square Error | 80.8T | |
| R-Squared | 0.56 | |
| Significance | 0.0006 | |
| Slope | 1,925,486 | |
| Total Sum of Squares | 2725.3T |
Universe Cash History
Other Fundumenentals of Universe Pharmaceuticals
Universe Pharmaceuticals Cash component correlations
Click cells to compare fundamentals
About Universe Pharmaceuticals Financial Statements
Universe Pharmaceuticals stakeholders use historical fundamental indicators, such as Universe Pharmaceuticals' Cash, to determine how well the company is positioned to perform in the future. Although Universe Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Universe Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Universe Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Universe Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Cash | 38.6 M | 40.6 M | |
| Cash And Short Term Investments | 38.6 M | 40.6 M | |
| Change In Cash | 4.7 M | 3.7 M | |
| Free Cash Flow | -4.9 M | -4.6 M | |
| Begin Period Cash Flow | 33.9 M | 35.6 M | |
| Total Cashflows From Investing Activities | -307.6 K | -323 K | |
| Other Cashflows From Financing Activities | -2.8 M | -2.6 M | |
| Other Non Cash Items | 426.2 K | 447.5 K | |
| Total Cash From Operating Activities | -4.5 M | -4.3 M | |
| Total Cash From Financing Activities | 11.2 M | 7.1 M | |
| End Period Cash Flow | 38.6 M | 40.6 M | |
| Other Cashflows From Investing Activities | -86.3 K | -90.6 K | |
| Free Cash Flow Yield | (425.08) | (403.83) | |
| Operating Cash Flow Per Share | -1.7 K | -1.6 K | |
| Free Cash Flow Per Share | -1.8 K | -1.7 K | |
| Cash Per Share | 8.7 K | 9.1 K | |
| Capex To Operating Cash Flow | (0.06) | (0.06) | |
| EV To Operating Cash Flow | 5.54 | 3.51 | |
| EV To Free Cash Flow | 5.18 | 6.18 | |
| Cash Ratio | 2.29 | 2.41 | |
| Cash Conversion Cycle | 257.42 | 270.30 | |
| Operating Cash Flow Sales Ratio | (0.33) | (0.31) | |
| Free Cash Flow Operating Cash Flow Ratio | 1.23 | 2.01 | |
| Cash Flow Coverage Ratios | (0.63) | (0.60) | |
| Cash Flow To Debt Ratio | (0.63) | (0.60) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Universe Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Universe Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Universe Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Universe Pharmaceuticals Stock:Check out the analysis of Universe Pharmaceuticals Correlation against competitors. For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Will Biotechnology sector continue expanding? Could Universe diversify its offerings? Factors like these will boost the valuation of Universe Pharmaceuticals. If investors know Universe will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Universe Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.82) | Earnings Share (7.83) | Revenue Per Share | Quarterly Revenue Growth (0.14) | Return On Assets |
The market value of Universe Pharmaceuticals is measured differently than its book value, which is the value of Universe that is recorded on the company's balance sheet. Investors also form their own opinion of Universe Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Universe Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Universe Pharmaceuticals' market value can be influenced by many factors that don't directly affect Universe Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Universe Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Universe Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Universe Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.